Dr. Levis On A Phase Ii Trial Examining Quizartinib In Aml

Dr. Levis on a Phase II Trial Examining Quizartinib in AML

Targeted Oncology

Dr. Levis Discusses Quizartinib in AML

Dr. Levis Discusses the Ideal Use of Quizartinib in FLT3-ITD AML

Dr. Levis on the Ideal Way to Use Quizartinib to Treat AML

Targeted Oncology

Dr. Levis on Quizartinib in AML Patients Without the FLT3-ITD Mutation

Targeted Oncology

Quizartinib in AML

Dr. Levis on the Background and Future of Quizartinib for AML

Targeted Oncology

Dr. Levis on the Challenges of Treating FLT3-ITD AML

Quizartinib, venetoclax, and decitabine in patients with FLT3-ITD AML: a Phase I/II trial

VJHemOnc – Video Journal of Hematology & HemOnc

Personal Experience Managing AML With Quizartinib

Phase Ib/II trial of quizartinib, decitabine and venetoclax in FLT3-ITD-mutated AML

VJHemOnc – Video Journal of Hematology & HemOnc

Levis: First-in-Human Phase 1/II Trial of ASP2215 for Leukemia

Cancer Therapy Advisor

Dr Erba on the Safety of Quizartinib By Treatment Phase and Age in FLT3-ITD–positive AML

Dr. Levis on the Challenges of Treating FLT3-ITD AML

Targeted Oncology

A Phase I/II study evaluating quizartinib plus decitabine and venetoclax in FLT3-mutated AML

VJHemOnc – Video Journal of Hematology & HemOnc

Progress for gilteritinib and quizartinib for AML in the first-line setting

VJHemOnc – Video Journal of Hematology & HemOnc

Quizartinib advances overall survival in acute myeloid leukaemia patients

Dr. Faderl Discusses Combining Chemotherapy and FLT3 Inhibitors in AML

Mark Levis, MD, on why the FLT3 target is important in AML

Quizartinib for frontline FLT3-ITD+ AML: updated results from the QuANTUM-First trial

VJHemOnc – Video Journal of Hematology & HemOnc